Methylomic deep sequencing of ovarian cancer reveals diagnostic and prognostic signatures: 2013 Annual Meeting of the Taiwan Genomic Medicine and Biomarker Society Symposium on Clinical Application of Genomic Medicine

Rui-Lan Huang; Hui Chen Wang; Hung-Cheng Lai

doi:10.1016/j.bgm.2013.08.022

Methylomic deep sequencing of ovarian cancer reveals diagnostic and prognostic signatures: 2013 Annual Meeting of the Taiwan Genomic Medicine and Biomarker Society Symposium on Clinical Application of Genomic Medicine

Rui-Lan Huang, Hui Chen Wang, Hung-Cheng Lai

研究成果: 雜誌貢獻 › 文章 › 同行評審

摘要

The heterogeneity of ovarian cancer requires biomarkers for personalized medicine. DNA methylation aberration is a hallmark of cancer. The attempt of using DNA methylation as biomarkers for prognosis prediction is appealing. Methylomic analysis using next generation sequencing technology has never been applied in ovarian cancer research. The present study for the first time is to explore the methylomics of ovarian cancer using this cutting edge technology.

原文	中文
頁（從 - 到）	125
頁數	1
期刊	Biomarkers and Genomic Medicine
卷	5
發行號	3
DOIs	https://doi.org/10.1016/j.bgm.2013.08.022
出版狀態	已發佈 - 9月 2013
對外發佈	是

UN SDG

此研究成果有助於以下永續發展目標

存取文件

10.1016/j.bgm.2013.08.022

http://www.sciencedirect.com/science/article/pii/S2214024713000919

引用此

Methylomic deep sequencing of ovarian cancer reveals diagnostic and prognostic signatures: 2013 Annual Meeting of the Taiwan Genomic Medicine and Biomarker Society Symposium on Clinical Application of Genomic Medicine. / Huang, Rui-Lan; Wang, Hui Chen; Lai, Hung-Cheng.
於: Biomarkers and Genomic Medicine, 卷 5, 編號 3, 09.2013, p. 125.

研究成果: 雜誌貢獻 › 文章 › 同行評審

@article{757b0993bc7b4f078a7dd03a60de11fb,

title = "Methylomic deep sequencing of ovarian cancer reveals diagnostic and prognostic signatures: 2013 Annual Meeting of the Taiwan Genomic Medicine and Biomarker Society Symposium on Clinical Application of Genomic Medicine",

abstract = "The heterogeneity of ovarian cancer requires biomarkers for personalized medicine. DNA methylation aberration is a hallmark of cancer. The attempt of using DNA methylation as biomarkers for prognosis prediction is appealing. Methylomic analysis using next generation sequencing technology has never been applied in ovarian cancer research. The present study for the first time is to explore the methylomics of ovarian cancer using this cutting edge technology.",

author = "Rui-Lan Huang and Wang, {Hui Chen} and Hung-Cheng Lai",

year = "2013",

month = sep,

doi = "10.1016/j.bgm.2013.08.022",

language = "中文",

volume = "5",

pages = "125",

journal = "Genomic Medicine, Biomarkers, and Health Sciences",

issn = "2214-0247",

publisher = "Elsevier BV",

number = "3",

}

TY - JOUR

T1 - Methylomic deep sequencing of ovarian cancer reveals diagnostic and prognostic signatures

T2 - 2013 Annual Meeting of the Taiwan Genomic Medicine and Biomarker Society Symposium on Clinical Application of Genomic Medicine

AU - Huang, Rui-Lan

AU - Wang, Hui Chen

AU - Lai, Hung-Cheng

PY - 2013/9

Y1 - 2013/9

N2 - The heterogeneity of ovarian cancer requires biomarkers for personalized medicine. DNA methylation aberration is a hallmark of cancer. The attempt of using DNA methylation as biomarkers for prognosis prediction is appealing. Methylomic analysis using next generation sequencing technology has never been applied in ovarian cancer research. The present study for the first time is to explore the methylomics of ovarian cancer using this cutting edge technology.

AB - The heterogeneity of ovarian cancer requires biomarkers for personalized medicine. DNA methylation aberration is a hallmark of cancer. The attempt of using DNA methylation as biomarkers for prognosis prediction is appealing. Methylomic analysis using next generation sequencing technology has never been applied in ovarian cancer research. The present study for the first time is to explore the methylomics of ovarian cancer using this cutting edge technology.

U2 - 10.1016/j.bgm.2013.08.022

DO - 10.1016/j.bgm.2013.08.022

M3 - 文章

SN - 2214-0247

VL - 5

SP - 125

JO - Genomic Medicine, Biomarkers, and Health Sciences

JF - Genomic Medicine, Biomarkers, and Health Sciences

IS - 3

ER -